Duration of Exercise Program in Interstitial Lung Diseases.

A Comparison Trial of Eight Weeks Versus Twelve Weeks of Exercise Program in Interstitial Lung Diseases.

We aimed to compare the functional results of the 8th week with the results of the 12th week of the exercise programs applied to the patients with ILD.

Study Overview

• Status: Completed
• Conditions: Interstitial Lung Disease
• Intervention / Treatment: Other: Exercise program

Detailed Description

Exercise programs (EP) have been shown to be the effective approach for functional outcomes in interstitial lung diseases (ILD). In many studies, the duration of exercise programs varies between 8-12 weeks. However, the optimal duration of exercise program is still unknown.

We aimed to compare the results of the 8th week with the results of the 12th week of the PR programs applied to the patients with ILD.

A total of 14 patients with ILD referred to our PR unit [11 idiopathic pulmonary fibrosis, 2 sarcoidosis (stage 3 and 4) and 1 nonspecific interstitial pneumonia] were included in the study. Pulmonary function test, arterial blood gas analysis, 6- minute walk test, mMRC dyspnea scale, quality of life questionnaires and hospital anxiety depression scale were performed before, at the 8th and 12th weeks after the exercise program applied to the patients twice a week.

• Study Type: Interventional
• Enrollment (Actual): 14
• Phase: Not Applicable

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Child; Adult; Older Adult
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Completed the 12 week exercise program
• Diagnosed with ILD

Exclusion Criteria:

• Not completed 12 week exercise program

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Other: Exercise program; Treatment group	Other: Exercise program; Exercise program including breathing control, pursed-lip breathing, diaphragmatic and thoracic breathing, aerobic and strengthening training

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Six minute walk test	It was performed in a 30-meter long corridor in accordance with American Thoracic Society criteria	6 minute

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Pulmonary Function Test	It was used for assessment of lung functions	20 minutes
Hospital Anxiety and Depression Inventory	It was used for assessment of anxiety and depression	20 minutes
mMRC	It was used for dyspnea that patients felt during their daily activities.	5 minutes
SGRQ	A disease-specific quality of life scale	30 minutes
SF-36 Health Survey	A health related quality of life scale	30 minutes

Collaborators and Investigators

• Sponsor: Izmir Katip Celebi University

Study record dates

Study Major Dates

• Study Start (Actual): January 1, 2014
• Primary Completion (Actual): January 1, 2016
• Study Completion (Actual): January 1, 2016

Study Registration Dates

• First Submitted: October 1, 2017
• First Submitted That Met QC Criteria: October 1, 2017
• First Posted (Actual): October 5, 2017

Study Record Updates

• Last Update Posted (Actual): October 5, 2017
• Last Update Submitted That Met QC Criteria: October 1, 2017
• Last Verified: October 1, 2017

More Information

Terms related to this study

• Keywords: exercise; duration
• Additional Relevant MeSH Terms: Respiratory Tract Diseases; Lung Diseases; Lung Diseases, Interstitial
• Other Study ID Numbers: IKC4

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No